{Reference Type}: Journal Article
{Title}: Management of Poorly Differentiated Thyroid Cancer and Differentiated High-Grade Thyroid Carcinoma.
{Author}: Alam IS;Patel KN;
{Journal}: Surg Clin North Am
{Volume}: 104
{Issue}: 4
{Year}: 2024 Aug
{Factor}: 3.537
{DOI}: 10.1016/j.suc.2024.02.005
{Abstract}: Thyroid carcinoma of follicular cell origin exists on a histopathologic and clinical spectrum. The authors focus on the category of tumors that fall between the very favorable well-differentiated thyroid carcinomas and the very unfavorable anaplastic thyroid carcinomas. These intermediately aggressive tumors include poorly differentiated thyroid carcinoma and the newly defined differentiated high-grade thyroid carcinoma. Both diagnoses require certain histopathologic requirements be met in order to accurately identify these tumors post-operatively. Management remains primarily surgical though adjunctive treatments such as molecular targeted therapies (eg, tyrosine kinase inhibitors) and differentiation therapy (to restore tumor response to radioactive iodine) are also becoming available.